Trial Profile

A Phase 1/2, Open-Label Study of ADXS-503 Alone and in Combination With Pembrolizumab in Subjects With Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 10 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

19 Jan 2023 According to an Ayala Pharmaceuticals media release, Advaxis merged with Ayala Pharmaceuticals to form Ayala Pharmaceuticals.
08 Jun 2022 According to an Advaxis media release, the company will present additional clinical and immune correlative data from this Phase 1/2 clinical trial of ADXS-503
08 Jun 2022 According to an Advaxis media release, results from this study published at the 2022 ASCO Annual Meeting in Chicago, IL

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com